203 related articles for article (PubMed ID: 18369014)
1. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee.
Kavanagh PM; Gilmartin JJ; O'Donnell J; O'Flanagan D
Ir Med J; 2008 Jan; 101(1):6-7. PubMed ID: 18369014
[No Abstract] [Full Text] [Related]
2. [Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].
Tomono K; Hashimoto S
Nihon Rinsho; 2005 Jan; 63 Suppl 1():573-8. PubMed ID: 15799420
[No Abstract] [Full Text] [Related]
3. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
[No Abstract] [Full Text] [Related]
4. Prescribing antitumor necrosis factor drugs to patients with heart failure.
Ziegelstein RC
Arch Intern Med; 2005 Jan; 165(1):118-9. PubMed ID: 15642887
[No Abstract] [Full Text] [Related]
5. [Proper usage of biologics for treatment of rheumatoid arthritis].
Murayama M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):894-8. PubMed ID: 19469085
[No Abstract] [Full Text] [Related]
6. Tuberculosis infections and tumor necrosis factor alpha antagonists.
Gan J; Manadan AM; Sequiera W; Block JA
Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
[TBL] [Abstract][Full Text] [Related]
7. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
Dinarello CA
J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
[TBL] [Abstract][Full Text] [Related]
8. [Rheumatoid arthritis: current status of therapy].
El Bahri DM; Meddeb N; Sellami S
Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
[TBL] [Abstract][Full Text] [Related]
9. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
10. Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients.
Nolan TJ; O'Connor MB; Bond U; Swan J; Phelan MJ
Rheumatol Int; 2013 Jul; 33(7):1907-8. PubMed ID: 22441967
[No Abstract] [Full Text] [Related]
11. Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis?
Fisher BA; Keat A
J Rheumatol; 2006 Oct; 33(10):1934-5. PubMed ID: 17014012
[No Abstract] [Full Text] [Related]
12. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
Hyrich KL; Silman AJ
J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
[No Abstract] [Full Text] [Related]
13. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.
Long R; Gardam M
CMAJ; 2003 Apr; 168(9):1153-6. PubMed ID: 12719321
[No Abstract] [Full Text] [Related]
15. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
[No Abstract] [Full Text] [Related]
17. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Scott DL; Kingsley GH
N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
[No Abstract] [Full Text] [Related]
19. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.
Serac G; Tubach F; Mariette X; Salmon-Céron D; Ravaud P; Lioté F; Laharie D; Ziza JM; Marguerie L; Bonnet C; Falgarone G; Nicolas N; Lortholary O; Chosidow O
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):726-9. PubMed ID: 22113472
[No Abstract] [Full Text] [Related]
20. [Changing clinicians' prescription patterns].
Reuther LØ; Christensen HR; Mikkelsen C
Ugeskr Laeger; 2009 Sep; 171(37):2655-6. PubMed ID: 19758512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
